Jean Boulle Group

What Jean Boulle Group does

Jean Boulle Group is a privately held diversified investment holding company founded in 1993 by Jean-Raymond Boulle and headquartered in Luxembourg. The group deploys capital across five main sectors: mining (anorthosite in Greenland, diamonds in Angola/Namibia/Madagascar/Canada, magnesium in the US, copper in Zambia), medical technologies (transcatheter valve replacement systems via VDYNE and the previously owned Tendyne), therapeutics (trained immunity nanobiologics via Trained Therapeutix Discovery), agriculture and renewable energy (sugarcane, bioethanol, and bagasse-based power via majority-owned Omnicane in Mauritius), luxury and hospitality (Sun King Diamond Coating and Lion Camp sustainable tourism), supplemented by a long-standing conservation program focused on endemic species in Mauritius.

The group's core technology assets are proprietary and patent-protected. VDYNE's transcatheter tricuspid valve replacement system is fully repositionable and retrievable, delivered via transfemoral catheter, and addresses a condition with no approved minimally invasive alternative. Tendyne, acquired by Abbott Laboratories for US$400M, was the world's first transcatheter mitral valve to receive CE Mark and FDA approval. Trained Therapeutix Discovery operates under exclusive license from Icahn School of Medicine at Mount Sinai to develop nanobiologics that regulate the innate immune system. Sun King Diamond Coating uses patented diamond luminescence technology developed with Akzo Nobel and Rolls-Royce for premium brand applications.

The group generates revenue through a diversified portfolio of operating subsidiaries, licensing and royalty streams from mining and medtech investments, and capital appreciation from exits and strategic stakes. Its customer base spans national governments, sovereign wealth funds, institutional investors, multinational corporations (e.g., Abbott), and enterprises across multiple continents. The group reaches counterparties through direct enterprise engagement, government and NGO partnerships, joint ventures with state-owned enterprises, and institutional co-investment arrangements rather than conventional product distribution channels.

Name

Jean Boulle Group

Legal name

Jean Boulle Group

Website

https://jeanboullegroup.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

Jean Boulle Group is a privately held, Luxembourg-based diversified investment holding company that deploys capital across mining, medical technologies, therapeutics, agriculture and renewable energy, luxury, and conservation, with portfolio subsidiaries including VDYNE, Greenland Anorthosite Mining, Omnicane, Trained Therapeutix Discovery, and Sun King Diamond Coating.

Ownership category

akta.pro rank

Product category

Diversified Investment Holdings

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Business Services (B2B) Growth Equity (FSANACAD)

akta.pro secondary industry

Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)

Keywords

• Diversified investment holdings
• Mineral exploration operations
• Transcatheter heart valves
• Renewable energy production
• Diamond coating technology

Headquarters

HQ city

Luxembourg

HQ country

Luxembourg

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Mining Investment Returns: Returns generated from mineral exploration and mine development across anorthosite (Greenland), diamonds (Angola, Namibia, Madagascar, Canada), magnesium (US), and copper (Zambia) through equity stakes, royalties, and mining licence proceeds.
2. MedTech Licensing and Exit Proceeds: Returns from medical technology development through equity stakes and licensing/acquisition exits. Notable exit: Tendyne Holdings acquired by Abbott Laboratories for US$400 million (including US$250 million cash at close, US$50 million at CE Mark, US$100 million at FDA approval).
3. Agriculture Operations: Revenue from sugarcane cultivation (~225,000 tonnes per annum), renewable energy generation (~30% of Mauritius' annual electricity, 40% of renewable bagasse-based energy), and bioethanol production (up to 24 million litres per year) via group company Omnicane Limited.
4. Luxury Products and Hospitality: Revenue from luxury diamond products (Sun King Diamond Coating brand), luxury real estate, hospitality operations (Lion Camp sustainable tourism in Africa), and responsible tourism.
5. Therapeutics Development: Returns from therapeutic technology development via Trained Therapeutix Discovery (TTxD) through equity stakes and potential licensing of trained immunity nanobiologics for cancer and infectious disease treatment.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

Jean Boulle Group is a diversified investment holding company that acquires assets and projects, optimizes structure, management, and development with private and public investment across mining, medical technology, therapeutics, agriculture, luxury goods, and conservation. The group deploys capital through portfolio companies including VDYNE (transcatheter tricuspid valve replacement), Tendyne (transcatheter mitral valve replacement, acquired by Abbott for US$400 million), Greenland Anorthosite Mining, Trained Therapeutix Discovery, Omnicane, Sun King Diamond Coating, and Lion Camp.

Product overview

Jean Boulle Group is a diversified investment holding company that operates across five main sectors: Mining, MedTech, Therapeutics, Agriculture, and Luxury. The company's MedTech portfolio includes proprietary heart valve technologies, notably the VDYNE Transcatheter Tricuspid Valve Replacement System for treating tricuspid regurgitation, and the Tendyne Transcatheter Mitral Valve Replacement System (acquired by Abbott for $400M). In therapeutics, Trained Therapeutix Discovery develops nanobiologics using trained immunity approaches for cancer and infectious diseases. The mining division includes Greenland Anorthosite Mining for anorthosite extraction and US Green Magnesium for domestic magnesium production. The agriculture sector features Omnicane's sugarcane cultivation and renewable energy operations in Mauritius, while the luxury division includes Sun King Diamond Coating technology and Lion Camp sustainable tourism. The group operates through investee companies rather than as a unified software platform.

Differentiator

Problem solved

Functional benefit

Brands

• VDYNE: Medical device company developing transcatheter tricuspid valve replacement (TTVR) system for treatment of tricuspid regurgitation
• Tendyne
• Sun King Diamond Coating
• Lion Camp
• Trained Therapeutix Discovery (TTxD)
• Omnicane
• Greenland Anorthosite Mining (GAM)

Quantifiable outcome

• 331 Mauritius Kestrels released into the wild from Kestrel Valley reserve since 1994, saving the species from near-certain extinction
• +6 more outcomes

Named customers9 records

Segments6 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• U.S. Department of Energy (DOE)coreStrategic or Co-development Partner · 26 February 2026US Green Magnesium, a wholly owned company of Jean Boulle Group and a critical minerals company focused on US-sourced magnesium metal production, was selected as an industry partner for the DOE's High-Performance Computing for Energy Materials Innovation Engine initiative. This collaboration supports the development of green magnesium production technologies.
• Giant Mineral Fields and African Holdings LimitedminorStrategic or Co-development Partner · 4 February 2025A strategic partnership was announced between Giant Mineral Fields (GMF) and African Holdings Limited (AHL) for copper exploration in Zambia. Jean Boulle Group is associated with this partnership as part of its broader mining investment activities.
• ENDIAMA (National Diamond Company of Angola)coreStrategic or Co-development Partner · 4 February 2025JBDM Ltd., a company controlled and managed by Jean Boulle Group, entered into a joint venture with ENDIAMA for the development of Angola's N'Dumba diamond concession. ENDIAMA is the state-owned National Diamond Company of Angola.
• International Finance Corporation (IFC)coreStrategic or Co-development Partner · 27 April 2024Omnicane (a Jean Boulle Group portfolio company) signed a Collaboration Agreement with the IFC (private sector arm of the World Bank Group) for a coal-to-biomass transition project, aiming to develop Omnicane's renewable energy capabilities and accelerate the shift from coal to sustainable biomass energy.
• U.S. Medical Institutions (VISTA-US Feasibility Study)coreStrategic or Co-development Partner · 24 April 2024VDYNE initiated the United States early Feasibility Study (VISTA-US) for evaluation of its Transcatheter Tricuspid Valve Replacement System in collaboration with US clinical sites, following FDA clearance. The study represents a key step toward US regulatory approval.
• Corporate Council on Africa (CCA)coreStrategic or Co-development Partner · 22 February 2021Jean Boulle Group has been involved with the Corporate Council on Africa since its creation in 1993 to promote US-Africa business and investment. Jean-Raymond Boulle became a CCA Board member in February 2021 and was confirmed as Vice Chairman in April 2024. The Group has sponsored the US-Africa Business Summits in Marrakech (2022) and Dallas (2024).
• Icahn School of Medicine at Mount SinaicoreTechnology or IntegrationTrained Therapeutix Discovery (TTxD) operates under an exclusive license from the Icahn School of Medicine at Mount Sinai to develop nanobiologics that regulate the innate immune system for the treatment of cancer and other major diseases. A preclinical study by TTxD's scientific founders was published in Cell in November 2020.
• University of Athens Medical School, Radboud University Medical Center, and Life & Medical Sciences Institute, University of BonnminorStrategic or Co-development PartnerA clinical trial by Trained Therapeutix Discovery Inc. was published in Cell as a collaboration between the University of Athens Medical School, Radboud University Medical Center, and the Life & Medical Sciences Institute, University of Bonn, demonstrating trained immunity's therapeutic potential for fighting cancers.
• Durrell Wildlife Conservation TrustcoreStrategic or Co-development PartnerJean Boulle Group has partnered with Durrell Wildlife Conservation Trust for over 25 years on wildlife conservation initiatives including Mauritius Kestrel protection, Saint Brandon archipelago conservation, and emergency reptile rescue following the Wakashio oil spill in Mauritius. Durrell's expertise in captive breeding at Jersey Zoo was critical for the reptile rescue mission.
• Mauritian Wildlife Foundation (MWF)coreStrategic or Co-development PartnerThe group has partnered with MWF for over 25 years on conservation projects including Kestrel Valley (200-hectare private nature reserve), Saint Brandon archipelago conservation research, and emergency rescue of Mauritian reptiles following the Wakashio oil spill. MWF is the largest NGO in Mauritius exclusively concerned with conservation of endangered species.
• BirdLife InternationalminorStrategic or Co-development PartnerJean Boulle Group has partnered with BirdLife International on conservation and eco-awareness initiatives in Mauritius and beyond. Nathalie Boulle has been a Founder Patron of BirdLife's Rare Bird Club since 2007 and received BirdLife's President's Medal in 2013.
• Australian Doctors for Africa (ADFA)minorStrategic or Co-development PartnerJean Boulle Group sponsors Australian Doctors for Africa (ADFA) which provides orthopaedic, gastroenterology, and urology services in Madagascar at General Hospital, Clinique St Lucque, Military Hospital, and University Hospital. Surgical and endoscopic equipment has been donated and local medical staff trained to ensure sustainable services.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Carlyle Group: Global alternative asset manager operating buyout, growth, credit, and infrastructure strategies across healthcare, industrials, and natural resources. Comparable as a broad incumbent in growth and special-situations investing including resource assets.
• KKR & Co. Inc. Global alternative asset manager operating across private equity, credit, infrastructure, and real assets. Comparable in deploying capital across resource, healthcare, and growth-stage opportunities, but operates at vastly greater scale with traditional fund structures.
• BPEA EQT: Asia-focused private equity and growth investor (formerly Baring Private Equity Asia), now part of EQT Group, that invests across healthcare, technology, and consumer sectors. Comparable as a growth equity investor in operating businesses with similar deal scale, though with a regional rather than global focus.
• TPG Inc. Global alternative asset manager with growth, buyout, credit, and real estate strategies. Comparable in deploying growth capital into healthcare and natural resources, with a similar pattern of taking significant equity stakes in operating companies.

Direct peers

• General Atlantic: Global growth equity firm that invests in high-growth companies across technology, healthcare, financial services, and consumer. Comparable to Jean Boulle Group's growth-stage capital deployment model, particularly in healthcare and technology, though structured as a traditional fund manager rather than a permanent-capital vehicle.
• Sofina SA: Belgian family-controlled investment company that holds diversified minority and majority stakes in growth-stage companies across consumer, healthcare, digital, and sustainable sectors. Comparable as a privately controlled, multi-sector investment holding with similar size and long-duration orientation.
• Exor N.V. Dutch-listed diversified investment holding company controlled by the Agnelli family that deploys long-duration capital across industries including healthcare, technology, and luxury. Directly comparable to Jean Boulle Group in structure: family-controlled, privately led, diversified across unrelated industries with significant operating stakes.
• Investor AB: Swedish diversified holding company controlled by the Wallenberg family that owns significant listed and unlisted industrial, healthcare, and financial stakes. Closely comparable as a multi-generational, family-controlled diversified investment vehicle with a similar mandate of long-horizon capital deployment.
• Compass Diversified Holdings: US-listed diversified holding company that owns and operates a portfolio of niche, market-leading businesses across consumer, industrial, and healthcare end markets. Comparable as a permanent-capital vehicle that acquires controlling stakes in operating businesses across unrelated sectors.
• LetterOne: Private diversified investment holding company backed by Mikhail Fridman that invests across healthcare, technology, energy, and retail. Highly comparable to Jean Boulle Group in being a privately controlled, multi-sector investment group with portfolio companies at varying stages of development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/jean-boulle-group

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jean Boulle Group